EN
ページタイトル画像

Dermatology

Overview

The mission of the department of dermatology in Chiba University is to provide a better environment and tools to achieve the following objectives and goals:

  1. To provide the most appropriate medical treatment for patients who visit our department.
  2. To help develop dermatologists with high ethical standards and responsibilities for patient care and always with skills to improve diagnostic and treatment techniques.
  3. To better understand a wide range of abnormal skin conditions in addition to normal skin by cutting-edge science and ultimately to develop better treatments.

Professor:
Takashi Inozume

TEL: +81-43-226-2505
FAX: +81-43-226-2128
e-mail:tinozume●chiba-u.jp
URL: http://www.m.chiba-u.ac.jp/class/dermatology/index.html

※　Please change "●" mark to at-mark if you send emails.

28.jpg

Research & Education

28図.jpg

・Our research interests are to understand anti-melanoma T-cell response.
Especially, we are focusing on the characteristics of melanoma specific tumor infiltrating T-cells (TILs) derived from responders of immune checkpoint inhibitors (ICIs), to develop the novel immunotherapy for melanoma.

Our current specific aims are:

  1. Identify the novel immune checkpoint molecules that control anti-melanoma T-cell response.
  2. Identify the markers specifically expressed on the melanoma specific TILs that play important roles in anti-melanoma immune response.
  3. Develop the methods to activate melanoma specific TILs selectively.

Recent Publications

  1. PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted T cell clonotypes. Nagasaki J, Inozume T, Togashi Y et al. Cell Rep. 2022;38:110331.
  2. TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment. Kawashima S, Inozume T, Togashi Y et al. J Immunother Cancer. 2021;9:e003134.
  3. Analysis of the Tumor Reactivity of Tumor-Infiltrating Lymphocytes in a Metastatic Melanoma Lesion that Lost Major Histocompatibility Complex Class I Expression after Anti-PD-1 Therapy. Inozume T, Yaguchi T, Togashi Y et al. J Invest Dermatol. 2019;139:1490-1496.